Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Inhibition of DGAT2 reduces steatosis, inflammation, and fibrosis in rodent models of NASH and reduces liver fat in clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · cited 4×
“Because excessive accumulation of lipid in the liver has been postulated to be a prerequisite for the development of NASH (4), we also evaluated the effects of PF-06427878 on the development of NASH using the STAM NASH-HCC mouse model.”
BackgroundMethodInfluentialThematic review series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis
Yen, C.-L. E., Stone, S. J., Koliwad, S., Harris, C., & Farese, R. V. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800018-jlr200 · Cited by 1,105
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cloning of DGAT2, a Second Mammalian Diacylglycerol Acyltransferase, and Related Family Members
Cases, S., Stone, S. J., Zhou, P., Yen, E., Tow, B., Lardizabal, K. D., Voelker, T., & Farese, R. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106219200 · Cited by 818 · cited 2×
“In mammals, two structurally unrelated DGAT enzymes, DGAT1 and DGAT2, have been characterized: DGAT1 is expressed abundantly in the intestine, where it plays a critical role in the absorption of dietary lipids (9), whereas DGAT2 is found in the liver and adipose tissue (9) and, unlike DGAT1, exhibits high substrate sp…”
BackgroundEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver
Monetti, M., Levin, M. C., Watt, M. J., Sajan, M. P., Marmor, S., Hubbard, B. K., Stevens, R. D., Bain, J. R., Newgard, C. B., Farese, R. V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.005 · Cited by 511 · cited 1×
“Conversely, overexpression of DGAT2 in the liver increases SREBP1 signaling (51).”
BackgroundChoi, C. S., Savage, D. B., Kulkarni, A., Yu, X. X., Liu, Z.-X., Morino, K., Kim, S., Distefano, A., Samuel, V. T., Neschen, S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704213200 · Cited by 383
Cited by
Highly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
“A small-molecule inhibitor of DGAT2 also reduced hepatic steatosis in both mice and humans with few adverse effects in pre-clinical studies and in two phase I clinical studies 289 .”
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219
Self-citationLuci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Metadata
- Authors
- Amin, N. B., Carvajal-Gonzalez, S., Purkal, J., Zhu, T., Crowley, C., Perez, S., Chidsey, K., Kim, A. M., & Goodwin, B.
- Venue
- Science Translational Medicine
- Published
- 2019-11-27
- Volume
- 11
- Issue
- 520
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2989941819
- Cited by
- 74
- References
- 17
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1126/scitranslmed.aav9701
- The paper
- Amin, N. B., Carvajal-Gonzalez, S., Purkal, J., Zhu, T., Crowley, C., Perez, S., Chidsey, K., Kim, A. M., & Goodwin, B. (2019). Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aav9701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.